Guang Fang Ji

Aristolochia fangchi Y.C.Wu ex L.D.Chow & S.M.Hwang

Also known as: Southern Fangji Root(English)

Kuang Fang Chi

Updated October 14, 2026 · Not yet clinically reviewed

Safety at a glance

High risk

Aristolochic acid — drug standard cancelled in China (国食药监注[2004]379号, 2004-08-05); not in the Chinese Pharmacopoeia 2020

High risk

Graded severe in our catalogue

Caution

6 recorded drug interactions, 5 major or contraindicated

Note

Contraindications or side effects are listed

No rule in our tables for this herb: pregnancy, breastfeeding, incompatible pairs (十八反 / 十九畏), herb–drug, dose ceiling. This is not a safety clearance.

Traditional Chinese Medicine

Category
transforming dampness
Temperature
Cold
Taste
Pungent,Bitter
Channels
Bladder,Lung,Spleen,Kidney

Functions

Expels Wind-Dampness and clears Heat; Promotes urination and reduces edema

Traditional uses

Safety warning: Guang Fang Ji is the root of Aristolochia fangchi and contains aristolochic acid, a nephrotoxin and carcinogen responsible for aristolochic acid nephropathy (notably the 1990s Belgian slimming-clinic cases) and urothelial carcinoma. Its medicinal standard was removed from the Chinese Pharmacopoeia in 2004 and it is banned in many countries; the description below is historical only and it must not be used.

It was formerly classed among the Dampness-dispelling herbs: pungent, bitter and cold, entering the Bladder, Lung, Spleen and Kidney channels, and used to expel Wind-Dampness while clearing Heat, and to promote urination and reduce edema. Because it shares the name element “Fang Ji,” it was dangerously confused with and substituted for Han Fang Ji (Stephania tetrandra), the intended safe herb for these indications.

Formulas using this herb

Botanical

Aristolochia fangchi is a woody, deciduous climbing vine of the Aristolochiaceae, native to subtropical broadleaf forests of southern China (notably Guangdong and Guangxi) and northern Vietnam. The slender twining stems may reach 5–10 m. Alternate, long-petioled leaves are oblong-ovate to narrowly cordate, 8–18 cm long, glabrous and dull green above with paler pubescence beneath. The bilaterally symmetrical pipe-shaped flowers, characteristic of the genus, are yellow-green flushed with purple-brown markings. The cylindrical, longitudinally six-ribbed capsule splits at maturity. The medicinal organ is the dried root, cylindrical or somewhat tortuous, with a thick yellow-brown bark and pale yellow woody centre. The species contains nephrotoxic aristolochic acids and is the documented causative agent of the Belgian 'Chinese-herb nephropathy' outbreak; it is now banned or withdrawn from medicinal use in most jurisdictions.

Pharmaceutical name
Radix Aristolochiae Fangji
Parts used
root
Plant type
vine

Constituents

Aristolochic acid I

Nitrophenanthrene carboxylic acid (aristolochic acid) · Principal aristolochic acid of the root; content varies widely between batches and commercial sources, so no batch can be assumed low

The compound responsible for the injury attributed to this drug. It is reduced by NQO1 and CYP1A1/1A2 to a cyclic N-acylnitrenium ion that forms persistent 7-(deoxyadenosin-N6-yl)-aristolactam I adducts in DNA, driving the A:T to T:A transversion signature found in aristolochic acid associated urothelial and hepatic tumours, and it is directly toxic to the renal proximal tubule, producing hypocellular interstitial fibrosis. The International Agency for Research on Cancer classifies aristolochic acid, and plants containing it, as carcinogenic to humans (Group 1). No threshold below which exposure is safe has been demonstrated.

Aristolochic acid II

Nitrophenanthrene carboxylic acid (aristolochic acid) · Second most abundant aristolochic acid in the root, generally below aristolochic acid I

Shares the nitroreduction and DNA-adduct pathway of aristolochic acid I and contributes to the total genotoxic burden of the drug. Analytical methods that quantify only aristolochic acid I therefore understate exposure.

Aristolochic acid IIIa

Nitrophenanthrene carboxylic acid (aristolochic acid) · Minor component of the root

A hydroxylated aristolochic acid recorded in this species by the IARC review of Aristolochia constituents. It is one reason total aristolochic acid content, rather than a single marker, is the relevant exposure measure.

Aristolactam I

Aristolactam (phenanthrene lactam) alkaloid · Present in the root

Both a native constituent and the reductive metabolite of aristolochic acid I. Its presence is used analytically as a marker of Aristolochia material, and aristolactam-DNA adducts are the biomarker used to establish past exposure in patients decades after ingestion.

Magnoflorine

Aporphine quaternary alkaloid · Present in the root

A quaternary aporphine alkaloid shared with several unrelated medicinal roots. It is of analytical rather than therapeutic interest here, because it is one of the fifteen alkaloids used to separate Aristolochia fangchi from Stephania tetrandra chromatographically.

Mufongchins A, B, C and D

Sesquiterpene-type constituents characteristic of the species · Minor constituents of the root

Constituents recorded specifically from Aristolochia fangchi in the IARC review of the species. They have no established pharmacology and are noted here only as species-characteristic markers.

Allantoin

Purine metabolite (imidazolidinyl urea derivative) · Minor constituent of the root

A widely distributed plant purine metabolite recorded in this root. It carries no clinical significance relative to the aristolochic acid content.

Beta-sitosterol

Phytosterol · Minor constituent of the root

A ubiquitous plant sterol recorded among the neutral constituents of the root, of no clinical relevance in this drug.

Tetrandrine

Bisbenzylisoquinoline alkaloid · Absent from Aristolochia fangchi; the marker of Stephania tetrandra, the drug this one is confused with

Listed here as a negative marker. Tetrandrine and fangchinoline are the characteristic alkaloids of Han Fang Ji (Stephania tetrandra); their absence, together with detectable aristolochic acid I, is what identifies a sample as Aristolochia fangchi. Analysis of twelve powder batches supplied to Belgian clinics as Stephania tetrandra found ten containing aristolochic acids only, one containing both, and one containing tetrandrine only.

Drug interactions

Han Fang Ji (Stephania tetrandra)

Major · Life-threatening and irreversible: end-stage renal failure and urothelial carcinoma · Evidence level: Established

This is the substitution that caused the Belgian slimming-clinic epidemic and is the principal route by which patients are exposed to this drug. Both roots are sold under the shared trade name fang ji, and they are morphologically similar in sliced form. Between 1990 and 1992 Belgian clinics dispensing a weight-loss regimen received consignments labelled Stephania tetrandra that were in fact Aristolochia fangchi; chemical analysis of the powders confirmed aristolochic acid where tetrandrine should have been. Roughly 100 patients developed rapidly progressive hypocellular interstitial renal fibrosis, about 70 percent of them reaching end-stage renal disease. Of 39 patients who went on to prophylactic nephroureterectomy, 18 were found to have urothelial carcinoma, with a positive dose-response relationship to the cumulative amount of the herb consumed. Renal function decline was proportional to the estimated ingested dose of the substituted material. The confusion runs in both directions: material sold as Han Fang Ji may be Aristolochia fangchi, and material sold as Guang Fang Ji may be Stephania tetrandra.

Clinical note: Do not treat these as interchangeable and do not accept a supplier's fang ji label. Aristolochia fangchi must not be dispensed at all. Where Stephania tetrandra is intended, require certificate-of-analysis evidence of tetrandrine and fangchinoline and of the absence of aristolochic acid I; the United Kingdom prohibition order bans Stephania tetrandra alongside Aristolochia precisely because the label cannot be trusted. Any patient with a history of fang ji or slimming-preparation use in the 1990s warrants renal function testing and lifelong urothelial surveillance regardless of current symptoms.

Mu Fang Ji (Cocculus orbiculatus and Cocculus trilobus)

Major · Identity failure leading to aristolochic acid exposure · Evidence level: Established

The name fang ji is shared by three unrelated drugs: Han Fang Ji from Stephania tetrandra (Menispermaceae), Mu Fang Ji from Cocculus orbiculatus or Cocculus trilobus (Menispermaceae), and Guang Fang Ji from Aristolochia fangchi (Aristolochiaceae). The three-way ambiguity is the mechanism of exposure, because a prescription or a supplier invoice reading simply fang ji does not determine which botanical source arrives. The United Kingdom prohibition order lists Cocculus laurifolius, Cocculus orbiculatus and Cocculus trilobus alongside Aristolochia and Stephania tetrandra for this reason.

Clinical note: Prescribe and purchase by binomial, never by the bare pinyin fang ji. Treat any consignment identified only as fang ji as of unknown botanical origin and unsuitable for dispensing until assayed for aristolochic acid I.

Guan Mu Tong (Aristolochia manshuriensis), Qing Mu Xiang (Aristolochia debilis) and Xi Xin (Asarum species)

Major · Additive and cumulative carcinogenic and nephrotoxic exposure · Evidence level: Established

Injury from aristolochic acid tracks cumulative lifetime dose, and every additional aristolochic-acid-bearing drug adds to it. Aristolochia manshuriensis substituted for Mu Tong caused a separate large series of end-stage renal disease in China, and Aristolochia debilis was used as Qing Mu Xiang; Asarum species contain lower but non-zero amounts. The Chinese regulator cancelled the drug standards for Guan Mu Tong in 2003 and for Guang Fang Ji and Qing Mu Xiang in 2004, and in the same 2004 notice required aristolochic acid warnings on preparations containing Aristolochia debilis fruit, Aristolochia mollissima, Aristolochia contorta stem and Aristolochia tuberosa. Aristolochia and Asarum species are also documented adulterants of one another and of unrelated drugs, so exposure may be unrecorded on any prescription.

Clinical note: Take a cumulative exposure history rather than asking about a single herb, and include Chinese proprietary medicines taken before the 2003 and 2004 standard cancellations. There is no dose at which co-administration becomes acceptable; the correct total exposure is zero.

Nonsteroidal anti-inflammatory drugs

Major · Accelerated loss of renal function in an already fibrotic kidney · Evidence level: Probable

Aristolochic acid nephropathy produces a hypocellular interstitial fibrosis with severe loss of proximal tubule mass and reduced renal reserve. Nonsteroidal anti-inflammatory drugs reduce prostaglandin-dependent afferent arteriolar vasodilatation and are an established cause of acute-on-chronic decline in patients with existing tubulointerstitial disease. Concomitant analgesic use was also examined as a confounder in the Belgian cohort and could not account for the lesion, which was attributed to aristolochic acid, but it remains an avoidable additional insult in exposed patients.

Clinical note: In any patient with known or suspected aristolochic acid exposure, avoid nonsteroidal anti-inflammatory drugs and other nephrotoxic agents including aminoglycosides, cisplatin, iodinated contrast and calcineurin inhibitors where alternatives exist, and monitor serum creatinine and estimated glomerular filtration rate.

Fenfluramine, diethylpropion, acetazolamide and meprobamate

Moderate · Investigated as cofactors in the original epidemic; not the established cause · Evidence level: Possible

The Belgian slimming preparation combined the substituted Chinese herb powders with appetite suppressants and other synthetic agents, and these were examined as possible contributors when the epidemic was first described in 1993. Subsequent identification of aristolochic acid in the powders, detection of aristolactam-DNA adducts in patient tissue, reproduction of the nephropathy in animals and the appearance of the same lesion in unrelated populations exposed to Aristolochia without any of these drugs established aristolochic acid as the cause. They are recorded here so that a patient history mentioning appetite suppressants is recognised as a marker of possible aristolochic acid exposure.

Clinical note: Treat a history of 1990s slimming-clinic preparations, particularly Belgian ones, as presumptive aristolochic acid exposure and investigate renal function and urothelium accordingly, even if the patient recalls only the synthetic drugs.

Ciclosporin and tacrolimus

Major · Additive nephrotoxicity; immunosuppression in patients at high urothelial cancer risk · Evidence level: Probable

Many patients injured by this drug progress to renal transplantation and then receive calcineurin inhibitors, which are themselves nephrotoxic to the graft. Independently, aristolactam-DNA adducts persist in urothelium for decades after exposure ends, so the risk of urothelial carcinoma continues in the transplanted patient while under immunosuppression. Urothelial tumours were found in 18 of 39 exposed Belgian patients undergoing prophylactic nephroureterectomy at the time of, or in preparation for, transplantation.

Clinical note: In transplant candidates with documented aristolochic acid exposure, urothelial assessment of the native urinary tract belongs in the pre-transplant workup, and surveillance must continue after grafting.

Dosage

FormAmountFrequencyNotes
not recommendedNot established — should not be dispensed—
**This drug should not be dispensed.** Guang Fang Ji (广防己) is the root of Aristolochia fangchi. All Aristolochia species contain aristolochic acid, which causes irreversible aristolochic acid nephropathy and urothelial carcinoma, and is an IARC Group 1 human carcinogen. This is the drug behind the Belgian slimming-clinic nephropathy cluster of the 1990s, in which more than 100 patients developed renal failure and many later urothelial cancer. It has no monograph in the Chinese Pharmacopoeia 2020 — the aristolochic-acid drugs were delisted — so no dose is given here and none is defensible. Safe substitutes that ARE in ChP 2020: Mu Tong (Akebiae Caulis, 3–6 g) replaces the Aristolochia 'mu tong' drugs, and Fang Ji (Stephaniae Tetrandrae Radix, 5–10 g) replaces the Aristolochia 'fang ji' drugs.

Evidence

Study design on record, not certainty of outcome.

Observational / case report
9

Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs

Vanherweghem JL, Tielemans C, Abramowicz D, Depierreux M, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, Jadoul M · The Lancet · 1993 · cohort

Observational / case report · Verified

The index report of the Belgian epidemic. Nine young women attending a Brussels slimming clinic developed rapidly progressive interstitial renal fibrosis; the regimen had been altered in 1990 to include powdered Chinese herbs nominally Stephania tetrandra and Magnolia officinalis. Renal biopsy showed extensive hypocellular interstitial fibrosis with tubular atrophy and relative sparing of glomeruli. The paper identified the herbal component of the regimen as the suspect exposure before the responsible compound was known.

doi:10.1016/0140-6736(93)92984-2

Urothelial lesions in Chinese-herb nephropathy

Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C · American Journal of Kidney Diseases · 1999 · cohort

Observational / case report · Not yet verified

Examination of the urinary tract in Belgian patients with end-stage Chinese-herb nephropathy found multifocal, high-grade atypia and carcinoma of the urothelium extending along the whole urinary tract, not confined to the kidney. This established that the lesion was a field change of the entire urothelium and provided the rationale for prophylactic removal of the native kidneys and ureters rather than surveillance alone.

doi:10.1016/s0272-6386(99)70136-8

Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi)

Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL · New England Journal of Medicine · 2000 · cohort

Observational / case report · Not yet verified

The decisive human study. Thirty-nine patients with end-stage Chinese-herb nephropathy who had taken the substituted preparation underwent prophylactic nephroureterectomy; 18 had urothelial carcinoma and a further 19 had mild to moderate urothelial dysplasia, so only 2 specimens were normal. The cumulative dose of Aristolochia fangchi ingested predicted the presence of carcinoma. Aristolactam-DNA adducts were detected in the tissue of the majority of patients tested, linking the tumours directly to aristolochic acid rather than to any other component of the regimen.

doi:10.1056/NEJM200006083422301

Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose

Martinez MCM, Nortier J, Vereerstraeten P, Vanherweghem JL · Nephrology Dialysis Transplantation · 2002 · cohort

Observational / case report · Not yet verified

Analysis of the Belgian cohort showed that the rate of decline in renal function was determined by the cumulative dose of the substituted Aristolochia fangchi material rather than by the duration of the slimming regimen or the other drugs it contained. This dose-dependence is the basis for treating any quantified exposure as clinically meaningful and for the absence of a demonstrated safe intake.

doi:10.1093/ndt/17.3.408

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, et al. · Proceedings of the National Academy of Sciences · 2007 · cohort

Observational / case report · Not yet verified

In Croatian patients with endemic nephropathy and upper urinary tract cancer, aristolactam-DNA adducts were found in renal tissue and A:T to T:A transversions were found in TP53 in tumours, matching the mutational fingerprint of aristolochic acid. The exposure route here was dietary contamination of wheat by Aristolochia clematitis seed, a different species from Aristolochia fangchi, which is important because it shows the same lesion arises from the aristolochic acid itself rather than from anything peculiar to the Belgian preparation.

doi:10.1073/pnas.0701248104

Aristolochic acid-associated urothelial cancer in Taiwan

Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP · Proceedings of the National Academy of Sciences · 2012 · cohort

Observational / case report · Not yet verified

In 151 Taiwanese patients with upper urinary tract urothelial carcinoma, aristolactam-DNA adducts were detected in 83 percent of renal tissue samples and the A:T to T:A TP53 signature in 44 of 60 tumours sequenced, in a population with exceptionally high prescribed use of aristolochic-acid-containing herbs. The study extends the risk from a single contaminated slimming regimen to routine prescribing of Aristolochia drugs.

doi:10.1073/pnas.1119920109

Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing

Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, et al. · Science Translational Medicine · 2013 · cohort

Observational / case report · Not yet verified

Whole-exome sequencing of upper urinary tract tumours from patients with documented aristolochic acid exposure found a very high somatic mutation burden dominated by A:T to T:A transversions at the sequence context characteristic of aristolactam-adenine adducts. The signature is specific enough to identify past aristolochic acid exposure from tumour DNA alone, which is how exposure is confirmed in patients who cannot recall what they took.

doi:10.1126/scitranslmed.3006200

Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool

Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, et al. · Science Translational Medicine · 2013 · cohort

Observational / case report · Not yet verified

Whole-genome sequencing of upper tract urothelial carcinomas defined the genome-wide aristolochic acid signature and showed it could be used to screen tumour series for unrecognised exposure. Applying it revealed aristolochic acid exposure in cases where no herbal history had been recorded, indicating that the exposed population is larger than clinical reporting suggests.

doi:10.1126/scitranslmed.3006086

Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia

Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W, Suzuki Y, Thangaraju S, Ng CCY, Tan P, Pang ST, Huang HY, et al. · Science Translational Medicine · 2017 · cohort

Observational / case report · Not yet verified

Screening 1400 hepatocellular carcinoma genomes across Asia found the aristolochic acid mutational signature in 78 percent of Taiwanese cases and substantial proportions elsewhere in Asia, versus about 5 percent in Europe and North America. This extends the organ risk beyond the urinary tract to the liver and shows the exposure is not historical or confined to one country.

doi:10.1126/scitranslmed.aan6446

Safety

Toxicity: severe

⚠ Rule-based cautions

These entries come from the deterministic rule tables that gate Verscienta's formula tools: classical pair prohibitions, pregnancy and lactation contraindications, dose ceilings, and drugs outside the Chinese Pharmacopoeia. The botanical-genus entries are different: advisory notes are not part of the safety screen; the Aristolochia genus check is.

Chinese Pharmacopoeia status

drug standard cancelled in China (国食药监注[2004]379号, 2004-08-05); not in the Chinese Pharmacopoeia 2020

drug standard cancelled (国食药监注[2004]379号, 2004-08-05, item 一); the notice replaced it with 防己 (Stephania tetrandra) in national-standard patent medicines by 2004-09-30, after which product still containing it is treated as counterfeit (假药)

国家食品药品监督管理局 国食药监注[2004]379号《关于加强广防己等6种药材及其制剂监督管理的通知》(2004-08-05)

Pending clinical review.

⚠ Toxicity

Compounds: Aristolochic acids I and II (nitrophenanthrene carboxylic acids), nephrotoxic and carcinogenic (IARC Group 1).

Cultural and historical

Shen Nong Ben Cao Jing · Eastern Han dynasty, compiled by the 2nd century CE

The name Fang Ji enters the materia medica here. The entry describes a drug name, not a botanical species, and cannot be read as referring to Aristolochia fangchi: the binomial did not exist and the classical text gives no character by which the Aristolochiaceae root could be distinguished from the Menispermaceae roots later sold under the same name. Nothing in this entry should be treated as evidence for using Aristolochia fangchi.

Ben Cao Gang Mu, Li Shizhen · Ming dynasty, 1596

Li Shizhen records that Fang Ji comprises more than one kind, distinguishing Han Fang Ji from Mu Fang Ji. This is an early written record of the naming ambiguity that later became the mechanism of injury, and it documents that practitioners have been unable to resolve fang ji to a single source plant for more than four centuries.

Pharmacopoeia of the People's Republic of China · Editions from 1963 to 2000

Guang Fang Ji (Radix Aristolochiae Fangchi) was carried as an official drug in successive Chinese pharmacopoeias through the 2000 edition. This is the reason the material entered international trade legitimately and why exposure histories from that era are common.

State Food and Drug Administration of China, document Guo Shi Yao Jian Zhu (2004) No. 379 · 2004

China cancelled the national drug standard for Guang Fang Ji, requiring that any national-standard formula containing it be reformulated with Fang Ji (Stephania tetrandra) of the 2000 Pharmacopoeia by 30 September 2004. The standard for Guan Mu Tong (Aristolochia manshuriensis) had been cancelled in 2003 and that for Qing Mu Xiang (Aristolochia debilis) in the same 2004 action. The herb has not appeared in the Chinese Pharmacopoeia since; the 2020 edition further removed Ma Dou Ling and Tian Xian Teng.

Belgian slimming-clinic case series, Brussels · 1990 to 1992, reported from 1993

Modern clinical record rather than a classical text, included because it is the defining event for this drug. Roughly 1500 to 2000 people followed a weight-loss regimen in which Stephania tetrandra was replaced by Aristolochia fangchi; about 100 developed interstitial nephropathy, around 70 percent of them progressing to end-stage renal failure, and urothelial carcinoma was found in 18 of 39 who underwent prophylactic nephroureterectomy. The injury is irreversible and the cancer risk persists for decades after exposure stops.

The Medicines (Aristolochia and Mu Tong etc.) (Prohibition) Order 2001, United Kingdom · 2001, in force 1 July 2001

Made the earlier temporary prohibition permanent, banning the sale, supply and importation of medicinal products for human use consisting of or containing any species of Aristolochia, and also Akebia quinata, Akebia trifoliata, Clematis armandii, Clematis montana, Cocculus laurifolius, Cocculus orbiculatus, Cocculus trilobus and Stephania tetrandra, together with extracts of them. Stephania tetrandra is included not because it is toxic but because it cannot be reliably distinguished in trade from Aristolochia fangchi.

References

  1. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. The Lancet. 1994 doi:10.1016/S0140-6736(94)90964-4
  2. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. The Lancet. 2001 doi:10.1016/s0140-6736(01)06576-x
  3. Schaneberg BT, Khan IA. Analysis of products suspected of containing Aristolochia or Asarum species. Journal of Ethnopharmacology. 2004 doi:10.1016/j.jep.2004.06.010
  4. Koh HL, Wang H, Zhou S, Chan E, Woo SO. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2006 doi:10.1016/j.jpba.2005.08.001
  5. Yuan J, Liu Q, Wei G, Tang F, Ding L, Yao S. Characterization and determination of six aristolochic acids and three aristololactams in medicinal plants and their preparations by high-performance liquid chromatography-photodiode array detection/electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry. 2007 doi:10.1002/rcm.3097
  6. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: A worldwide problem. Kidney International. 2008 doi:10.1038/ki.2008.129
  7. Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, Simmonds MSJ, Cook HT, Vanherweghem JL, Nortier JL, Lord GM. The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy. Annals of Internal Medicine. 2013 doi:10.7326/0003-4819-158-6-201303190-00006
  8. Tankeu S, Vermaak I, Chen W, Sandasi M, Viljoen A. Differentiation between two "fang ji" herbal medicines, Stephania tetrandra and the nephrotoxic Aristolochia fangchi, using hyperspectral imaging. Phytochemistry. 2016 doi:10.1016/j.phytochem.2015.11.008
  9. Jadot I, Decleves AE, Nortier J, Caron N. An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. International Journal of Molecular Sciences. 2017 doi:10.3390/ijms18020297
  10. Das S, Thakur S, Korenjak M, Sidorenko VS, Chung FFL, Zavadil J. Aristolochic acid-associated cancers: a public health risk in need of global action. Nature Reviews Cancer. 2022 doi:10.1038/s41568-022-00494-x
  11. International Agency for Research on Cancer. Plants Containing Aristolochic Acid. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100A: Pharmaceuticals. 2012
  12. International Agency for Research on Cancer. Aristolochia species and aristolochic acids. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 82: Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. 2002
  13. United Kingdom Secretary of State for Health. The Medicines (Aristolochia and Mu Tong etc.) (Prohibition) Order 2001. UK Statutory Instruments 2001 No. 1841. 2001
  14. State Food and Drug Administration of China. Notice on strengthening the supervision and administration of Guang Fang Ji and five other medicinal materials and their preparations. State Food and Drug Administration document Guo Shi Yao Jian Zhu (2004) No. 379. 2004
  15. United States Food and Drug Administration. Import Alert 54-10: Detention Without Physical Examination of Bulk/Finished Dietary Supplement Products Containing Aristolochic Acid. US Food and Drug Administration Import Alerts. 2020

Look-alike names

  • Han Fang Ji防己— Listed among herbs confused through similar names; the European slimming-drug nephropathy cases are attributed there to Aristolochia fangchi (Guang Fang Ji) given where Stephania tetrandra (Fang Ji) was meant.
© Verscienta Health — use subject to the API terms at https://verscienta.com/developers/api; educational reference, not medical advice